Press Release Date: October 3, 2000
Dietary use of garlic may lower some types of cholesterol in the short term,
but it does not appear to offer long-term protection against cardiovascular
disease, says a new evidence report released today by the Agency for Healthcare
Research and Quality (AHRQ). Garlic may help to reduce low-density lipids (LDL),
or "bad" cholesterol and triglycerides. However, the evidence is only for
short-term (1 to 3 months) effects. The long-term benefits have not been
determined. The levels of high-density lipids (HDL), or "good" cholesterol, were
unaffected. After 6 months, no further reductions in either triglycerides or LDL
were apparent. The report calls for additional research to examine the
short-term benefits versus the long-term benefits of garlic consumption.
The authors found no evidence that garlic has a beneficial impact on blood
pressure or diabetes. The evidence was inconclusive about garlic's role in
protecting against cancer. Dietary garlic may possibly be associated with
decreased likelihood of some types of cancer, but the number of available
studies was not sufficient to draw conclusions.
Another limitation of the current evidence is that research does not
sufficiently address the variations in garlic preparations, such as raw, cooked
or supplement form. Types of garlic and garlic preparations vary widely. As a
supplement, it is available dehydrated in tablets and as extracts, oils, and in
combination with other supplements.
The report, which was based on a systematic review and analysis of scientific
evidence related to clinical studies of garlic in humans, was conducted for AHRQ
by the San Antonio
Evidence-based Practice Center at The University of Texas Health Science
Center at San Antonio and the Veterans Evidence-based Research, Dissemination,
and Implementation Center (VERDICT), a Veterans Affairs Health Services Research
and Development Center of Excellence. It was requested by the National Center
for Complementary and Alternative Medicine, a component of the National
Institutes of Health. To arrange interviews with researchers at VERDICT, contact
Jennifer Arterburn, at (210) 617-5300, ext. 4028.
The summary of Evidence Report Number 20, Garlic: Effects on
Cardiovascular Risks and Disease, Protective Effects Against Cancer, and
Clinical Adverse Effects, is available through AHRQ's Web site at http://www.ahrq.gov/clinic/garlicsum.htm.
Print copies are available from the AHRQ Publications Clearinghouse at P.O. Box
8547, Silver Spring, MD 20907-8547, or 800-358-9295 within the U.S. or (410)
381-3150 from outside the country. A copy of the full report will be available
in winter 2000.
For more information, contact AHRQ Public Affairs (301) 594-1364: Jane
Steele, (301) 594-6350 (JSteele@ahrq.gov).